NCT01246063View on ClinicalTrials.gov

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 14, 2012

Primary Completion Date

December 28, 2017

Study Completion Date

March 23, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

carfilzomib

DRUG

pegylated liposomal doxorubicin (PLD)

DRUG

Dexamethasone

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01246063 - Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter